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Abstract 
Graft failure occurs in a sizeable proportion of coronary artery bypass conduits. We review the current 
evidence in order to give an overview of the incidence, pathophysiology, and clinical consequences of 
this multifactorial phenomenon. Thrombosis, endothelial dysfunction, vasospasm, and oxidative stress 
are different mechanisms associated with graft failure. Intrinsic morphologic and functional features of 
the bypass conduits play a role in determining of graft failure.  Characteristics of the target coronary 
vessel such as the severity of stenosis, the diameter, the extent of atherosclerotic burden, and previous 
endovascular interventions are important determinants of graft failure and must be taken into account 
at the time of surgery. Technical factors such as the method used to harvest the conduits, the 
vasodilatory protocol, and the storage solution as well as the anastomotic technique also play a major 
role. Systemic vascular risk factors such as age, gender, diabetes, hypertension, and dyslipidemia have 
been variably associated with graft failure. The correlation between graft failure and clinical events is 
less strict than commonly believed and varies according to the type and location of the failed graft. 
Intraoperative flow verification and secondary prevention using antiplatelet and lipid-lowering agents 
can help reducing the incidence of graft failure.  
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Long-term graft patency is the primary aim of coronary artery bypass surgery (CABG). 
Graft failure is a complex, multifactorial event that occurs in a substantial proportion of CABG conduits.  
With the aim of contributing to a better understanding of this phenomenon, we present a review of the 
current evidence on the biological, technical, and local factors that predispose a graft to failure. In 
addition, we review the published evidence on the clinical implications of graft failure and discuss 
possible preventive strategies. 
Literature Search  
The ATLANTIC (ArTeriaL grAftiNg inTernatIonal Consortium) Alliance is an international group of experts 
in CABG with a particular focus on the use of arterial grafts. In November 2016, the members of 
ATLANTIC searched PubMed using the terms “graft patency”, “graft failure” coupled with “coronary 
surgery”, “myocardial revascularization”, “coronary artery bypass”, “CABG”, “morphology”, “vascular 
biology”, “intraoperative detection” and “prevention”. Relevant abstracts were reviewed and the 
related articles function used for all included manuscripts. References from selected studies were cross-
checked. After collegial discussion, the most important papers were selected and form the basis of the 
present review. 
Patency of Different Conduits  
The incidence of graft failure is different for the various types of conduits used in CABG (Table 1). 
Great Saphenous Vein 
The patency of saphenous vein grafts (SVGs) at 1-year has been reported to range from 81 to 98%.1–3 It 
is worth noting that one modern trial, the Project of Ex Vivo Vein Graft Engineering via Transfection IV, 
(PREVENT IV), reported a SVG patency of only 75% at 12-18 months.4 Mid-term patency of SVGs, 
between 5 to 7 years, was reported to be 75-86%.1,2,5,6 Late SVG patency is severely reduced at ≥10-year 
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follow-up with studies reporting patency rates of 55-60% .1,7,8 A large Veteran Affair (VA) trial assessed 
SVG and left internal thoracic artery (LITA) graft patency in 1,074 and 457 patients, respectively. The 10-
year patency was 61% for veins and 85% for arterial grafts (p<0.001). If a graft was patent at 1 week, 
that graft had a 68% (SVG) and 88% (LITA) chance of being patent at 10 years (p<0.001).8 A network 
meta-analysis comparing all conduits used for CABG has shown that compared to the RA and the RITA 
SVGs have a 3- to 4-fold higher risk of occlusion after 4-years.5 The attrition rate of SVG is 1-2%/year 
between 1 to 6 years and 4%/year between 6 to 10 years.9 However, some groups have reported 
substantially superior SVG angiographic outcomes using an atraumatic harvesting method or a 
composite graft technique.10,11 
Internal Thoracic Artery 
Since the mid-1980s the use of the LITA for left anterior descending artery (LAD) grafting has been a 
cornerstone of CABG surgery. The patency of the LITA at 1 year has been reported to be 93-96%3,8,12, at 
5 years 88-94%,2,8,12 and >10 years 85-90%.8,12  Tatoulis et al.13 reported patency rates for the LITA and 
right internal thoracic artery (RITA) at 5, 10, and 15 years to be 98% and 96%, 95% and 81%, 88% and 
65%, respectively. In this study, the LITA was predominantly targeted to the LAD while the RITA was 
commonly grafted to the right coronary artery (RCA) followed by the circumflex territory. The lower 
patency of the RITA was likely due to the poor patency of the RITA-RCA/posterior descending artery 
(PDA) target (overall conduit/target, patency: LITA/LAD, 97%; RITA/LAD, 95%; RITA/RCA or PDA, 83%).13 
Internal thoracic arteries (ITAs), left or right, seem to have the best patency rates when targeted to the 
LAD, followed by diagonal, circumflex, and the RCA territory.13 The leading mechanistic explanation is 
competitive flow between the graft and the native coronary circulation. Given that dominant RCAs are 
usually larger diameter vessels than the LAD or circumflex, a bigger RCA without a high-grade proximal 
stenosis may continue to have substantial flow. In addition, the LAD is technically an easier target with 
more outflow, which are all factors contributing to excellent ITA to LAD patency.12  The RITA may be 
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used as a free graft without compromising patency; either as an aorto-coronary graft or as a composite 
graft based on the LITA13  
Radial Artery 
The 1-year patency of the radial artery (RA) has been reported to be 89-92%2,3, with the mid-term 
patency (≥5 years) being 90-98%.2,6,14 A meta-analysis reported radial patency beyond 4 years to be 
90%.5 Achouh et al.15 reported a 20-year angiographic patency of 83% and attrition rate of 0.4%/year 
after the first year up to 20 years. Gaudino and colleagues16 reported 85% patency rate at 20 years and 
25±0.2% probability of graft failure at 20 years for the RA compared to 19.0±0.2% for the LITA and 
55.0±0.2% for SVG (p=0.002 for RA vs. SVG, 0.11 for RA vs. ITA, and p<0.001 for ITA vs. SVG). The Radial 
Artery Patency and Clinical Outcomes randomized trial (RAPCO)17 presented their late results at the 
2016 American Association of Thoracic Surgery meeting ; 10-year patency of the RA was reported to be 
89-91%. Similar to ITAs, an important predictor of early and late patency for the RA is the severity of 
proximal native disease.18  
Right Gastroepiploic Artery 
There is limited data regarding right gastroepiploic artery (RGEA) patency. Early 1-year patency was 
reported to be 92-97%,19 80-90% at 5 years,20 and 62% at 10 years.20 These relatively low long-term 
patency rates are improved by using skeletonization and more restrictive criteria for target vessel 
stenosis (95% and 90% cumulative patency rates at 5 and 8 years, respectively).19 
In conclusion the incidence of graft failure varies with the type of conduits used for CABG. Arterial grafts 
have higher patency rates compared to SVGs, especially at long-term follow-up. 
Biological mechanisms underlying graft failure.  
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Graft failure being significantly more common in venous than arterial grafts, most of the known 
mechanisms have been described in SVGs. Even though graft failure is a single term describing graft 
stenosis and occlusion, the underlying mechanisms can vary, particularly in the early vs. late stages 
following implantation. The pathophysiology of vein graft failure has been attributed to acute 
thrombosis within the first month, intimal hyperplasia up to 1 year, and atherosclerosis beyond 1 year21 
(Figure 1). Different mechanisms are associated for each time frame, however, all contribute to graft 
occlusion.  
Mechanisms of Acute Thrombosis 
Early graft failure is caused by acute thrombosis, secondary to either direct endothelial injury or 
endothelial activation leading to a pro-thrombotic phenotype.22 De-endothelialization as a result of 
mechanical forces is predominantly seen in free grafts, such as SVGs.23 This results in exposure of the 
underlying extracellular matrix, local release of tissue factors as well as reduced bioavailability of 
prostacyclin and nitric oxide (NO), all of which contribute to platelet aggregation, deposition of fibrin, 
and ultimately thrombus formation.24 At the same time, activated platelets express several pro-
thrombotic molecules on their surface, such as P-selectin, and secrete substances with potent paracrine 
effects, such as platelet-derived growth factor, von-Willebrand factor, and the CD40 ligand, all 
promoting thrombosis as well as local inflammation through leukocyte chemotaxis and vascular wall 
infiltration.22 Intact endothelial cells may also be activated due to stress experienced during the 
operation, transient ischemia, or systemic triggers, such as diabetes. Expression of a series of pro-
thrombotic molecules on the luminal surface as well as impaired mechanisms of endothelial-dependent 
vasorelaxation combined with a shift towards the production of pro-thrombotic molecules (e.g. 
thromboxane A2 (TXA2), plasminogen activator inhibitor-1) all promote the interaction of the activated 
endothelial cells with circulating platelets and leukocytes, which initiate the inflammatory and 
thrombotic cascade responsible for graft thrombosis and failure.25  
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Impaired endothelial function 
The vascular endothelium is a source of a number of molecules with either vasorelaxant (e.g. NO) or 
vasoconstrictive properties (e.g., endothelin); the balance of which ultimately regulates the vascular 
tone.26,27 However, NO exerts pleiotropic effects by not only regulating the vascular tone through 
activation of guanyl-cyclase in the underlying vascular smooth muscle cells (VSMCs) but also by 
suppressing local inflammation, thrombosis, and protecting against oxidative injury.27 Interestingly, NO 
bioavailability appears to be greater in arterial compared to venous grafts, providing a possible 
explanation for the better outcome rates observed with arterial grafts.28 However, endothelial function 
varies even between different arterial types,26 with higher endothelial NO synthase (eNOS) expression 
partly explaining the greater NO-mediated vasorelaxations in ITA compared to RA grafts.29 Nevertheless, 
recent evidence suggests that high eNOS expression is not necessarily beneficial, given that in the 
presence of high levels of oxidative stress, depletion of the eNOS cofactor tetrahydrobiopterin can result 
in eNOS uncoupling and an increased production of superoxide (O2.-) anions resulting in endothelial 
dysfunction.30  
Vasoconstriction and spasm 
Both arterial and vein grafts are susceptible to the effects of vasoactive substances, such as endothelin, 
TXA2, serotonin, and α1-agonists.31 These vasoconstrictors come either from the systemic circulation or 
are generated inside the vascular wall by endothelial cells, VSMCs, or infiltrating inflammatory cells.26 
However, the response of different conduits to vasoconstrictors varies, highlighting the biological 
heterogeneity of the different conduits used in CABG.26 For example, variations in the presence and 
relative dominance of adrenergic receptors in VSMCs may explain why certain conduits (i.e., RA) are 
more prone to vasospasm than others.26  
Other biological factors: the role of oxidative stress and morphological characteristics 
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Effects of the vascular redox state on vascular disease are well-documented and several studies have 
implicated the production of reactive oxygen species (ROS) in disease progression in both arterial and 
vein grafts.32 ROS possess both direct deleterious effects on the vascular wall and also upregulate 
vascular inflammation through the activation of redox-sensitive pro-inflammatory pathways.33  In 
addition, the relative absence of endogenous antioxidant protective mechanisms in SVGs compared to 
ITAs might contribute to their worse patency rates.32   
 In addition, structural characteristics of arterial and venous conduits have also been linked to 
their susceptibility to graft failure. For example, the relative absence of an internal elastic lamina in 
combination with high intercellular junction permeability in SVGs accelerates atherosclerosis through 
infiltration by circulating leukocytes and lipoprotein deposition.23 In addition, exposure to the high 
pressure of arterial circulation results in early, diffuse intimal thickening as a compensatory response, 
termed “arterialization”.35 On the other hand, variations in the wall structure of arterial grafts  (e.g. 
muscular wall phenotype in RA grafts compared to a more elastic phenotype in ITA) might also explain 
differences in patency rates with different graft types.36    
Systemic Risk Factors 
Most systemic risk factors have deleterious effects on local vascular biology and promote a pro-
atherogenic phenotype. In addition, other systemic factors (e.g. platelet reactivity, age) might affect the 
individual response to post-CABG medical therapy, therefore increasing the risk for early or late graft 
failure.37 
Diabetes mellitus is associated with persistent platelet activation, endothelial dysfunction, increased 
VSMC reactivity to vasoconstriction, and accelerated intimal hyperplasia in SVG.34,38 The impact of 
diabetes on arterial and venous grafts has been investigated by several authors with most2,12,39, but not 
all40,41, showing a detrimental effect on graft patency. In a sub-analysis of the Radial Artery Patency 
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Study (RAPS), Desai and colleagues evaluated 440 RA grafts and 440 SVG. For all grafts, diabetes was 
demonstrated to be a predictor of graft occlusion at 1 year (Relative risk (RR):1.45, 95% confidence 
interval (CI) 1.03-2.05; p=0.03).39 Diabetes plays a different role depending on the type of graft used. In 
another sub-analysis of the same trial, Deb et al.18 showed that in diabetic patients the proportion of 
complete graft occlusion was significantly lower for RA grafts than for SVGs (p=0.0004), whereas this 
was not true for non-diabetic patients (p=0.19). Of note, interaction between diabetic status and 
conduit type was also statistically significant (p=0.02), suggesting that SVG do poorly in diabetics when 
compared to arterial grafts.  
Harskamp and colleagues recently evaluated the determinants of ITA graft failure in a cohort of 1,539 
CABG patients undergoing angiographic follow-up from the PREVENT-IV trial.41 Surprisingly, the only 
patient-specific predictor of ITA graft failure was the absence of diabetes (Odds Ratio (OR):1.86, CI 1.22-
2.81; p=0.004). 
Shah and colleagues40 in a study involving 3,715 angiograms, failed to show a predictive value of 
diabetes on graft failure (OR:1.12, CI 0.81-1.55; p=0.5).  
As most of the clinical trials on CABG mainly enrolled men, the role of gender is difficult to evaluate.42 
However, the influence of gender on patency based on the type of conduit used has been suggested. In 
the quoted sub-analysis of the RAPS trial, RA graft occlusion at 1 year occurred in similar proportions of 
men (8.6%) and women (5.3%) (p= 0.6), whereas occlusion rates for the SVG were 12.0% and 23.3%, 
respectively (p=0.02).39   
In the same study, traditional cardiovascular risk factors like age, preoperative myocardial infarction, 
hypertension, elevated lipids, smoking status, and peripheral vascular disease were not predictive of 1-
year graft failure. Of note, however, in the more recent 5-year report of the same trial, female sex 
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(OR:2.23, CI 1.14-4.38; p=0.02), smoking history (OR:1.49, CI 1.01-2.21; p=0.047) and elevated creatinine 
levels (OR:1.17, CI 1.02-1.35; p=0.03) were found to be independent predictors of graft failure.39  
A large angiographic series found no association between the classical vascular risk factors and graft 
patency.40 However, in the 10-year VA angiographic study, age (acceleration factor (AF):1.28; CI 1.04-
1.58; p=0.02), cholesterol levels (AF:0.76; CI 0.60-0.96; p=0.02) and Canadian Functional Class II-IV 
(AF:0.64; CI 0.40-1.02; p=0.05) were predictors of long-term graft status.8 Finally, in a sub-analysis of the 
PREVENT-IV trial, cerebrovascular disease was the only systemic predictor of graft patency (OR:1.35; CI 
1.04-1.77; p=0.03).4 
In conclusion the classical vascular risk factors, particularly diabetes, seems to play a role in determining 
graft failure, although the correlation between individual risk factors and graft outcome needs further 
investigation.   
Clinical Consequences of Graft Failure 
The association between graft failure and clinical outcome has not been as clearly proven as commonly 
believed. Different studies have in fact reported discordant results. 
Lytle et al. compared long-term survival of a cohort of 1,296 patients with (723) and without (573) SVGs 
stenosis.43 At a mean follow-up of 6.9 years, patients with vein graft stenosis occurring within 5 years 
and patients with no vein graft stenosis had similar outcomes. However, patients with significant 
stenosis in SVGs to the LAD had higher rates of death and cardiac events.  
In a large angiographic study on more than 5,000 grafts vein graft patency and occlusion were closely 
correlated with need for reoperation and survival.1  
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An analysis from the Duke Cardiovascular Databank reported the clinical impact of early vein graft 
failure in 1,243 patients who underwent angiography after CABG.44 The investigators found that SVG 
graft failure was associated with death, myocardial infarction, or revascularization (p<0.0001 for all). 
The results of the long-term follow-up study of the PREVENT IV trial showed that SVG failure was 
associated with an increase in revascularization but not with death and/or myocardial infarction.45  
In a large angiographic study, Shavadia et al. found that LITA-to-LAD graft failure but not GSV graft 
failure was associated with a worse long-term prognosis.46 In the PREVENT IV trial, LITA-to-LAD graft 
failure was also associated with a significantly higher incidence of acute clinical events, mostly as a result 
of a higher rate of repeat revascularization (HR:3.92, CI, 2.30-6.68; p<0.0001).41 
In an analysis of the RAPS trial examining late angiographic follow-up, Yamasaki and co-authors found 
that the incidence of adverse clinical events and need for revascularization was significantly higher in 
patients with graft stenosis (p<0.0001 and p<0.0009, respectively).47  
The lack of a constant correlation between graft failure and clinical event is likely related to the different 
amount of myocardium supplied by the failed graft. 
Other possible explanations are the high rate of non-flow limiting stenosis bypassed when using 
standard angiography for planning the grafting strategy48 and the possible development of a collateral 
network from other patent grafts. 
In conclusion the clinical consequences of graft failure seem to vary according to the location of the 
distal anastomosis, with graft to the LAD more closely related to clinical events. Further investigation is 
required to clarify the correlation between graft occlusion and clinical outcome and to elucidate the 
pathophysiologic mechanisms of this correlation. 
Pharmacological Preparation and Graft Storage 
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Almost all vasodilator agents have been used to prevent graft spasm before usage.48 Papaverine, 
nitrates, calcium antagonists, phosphodyesterase inhibitors, phenoxybenzamine, and iloprost have been 
proposed. Less frequently used vasodilators include Rho-kinase inhibitors, angiotensin receptor 
antagonists, potassium channel openers, heme-oxygenases, C-type natriuretic peptides, TXA2 
antagonists, and antiplatelet agents.48 Drugs acting through different mechanisms used in antispastic 
protocols include L-carnitine, botulinum toxin, and NO-independent guanylate cyclaseactivator YC-1 or 
NO-nucleophile adduct diethylamine/NO.48   
Vasodilator drugs relax the vessel through a very specific mechanism(s) (Figure 2) and, due to the 
complex and variable physiopathology of graft spasm, there is no “perfect” vasodilator. For this reason a 
common approach is to combine agents that target different mechanisms of spasm. The most used 
combinations is a calcium channel blocker (usually verapamil or nicardipine) combined with a NO-
releasing drug such as nitroglycerin.49–51 The addition of a systemic calcium channel antagonist is of 
questionable benefit.50,52 
The antispastic protocol should also include an atraumatic harvesting technique that protects the 
endothelium and smooth muscle cells of the media. 
Few studies have correlated the vasodilatory protocol used for graft preparation with patency. 
Yoshizaki and coworkers reviewed angiographic results among 116 CABG patients who had RA grafts 
and were treated either with verapamil-nitroglycerin or papaverine.53 Results showed that papaverine 
was significantly associated with RA graft occlusion. Among patients randomized to either continue or 
suspend diltiazem therapy 1 year after RA grafting, Gaudino and colleagues showed that at 5-year 
follow-up there was no difference in angiographic patency rates between groups.54  
The solutions in which grafts are stored before use also plays a crucial role. Storage solutions include 
normal saline, blood-based, heparinized, and buffered solutions. Numerous studies demonstrate the 
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detrimental effect of normal saline solutions on endothelial function and clinical outcomes. Wise and 
colleagues showed that grafts stored in normal saline have significantly reduced endothelial-dependent 
and -independent vasodilation (p=0.005 and p=0.002, respectively).55 Follow-up data from the PREVENT 
IV trial showed that 1-year vein graft failure rates were significantly lower when buffered saline, instead 
of saline or blood, was used (OR:0.63, CI 0.49-0.79; p<0.001 and OR:0.63, CI 0.48-0.81; p<0.001, 
respectively).56  
For arterial grafts the addition of pharmacologic agents to the storage solution has the potential to 
prevent graft spasm.50,51 
In the PREVENT IV trial ex vivo treatment with edifoligide (E2F decoy, regulates expression of genes 
controlling SMC proliferation) has been shown to be ineffective in the prevention of early vein graft 
failure.57 
Preoperative pharmacologic treatment with vitamin-C and cerivastatin has been proposed in order to 
achieve maximal vasodilatation and endothelial preservation of the RA.52 Adenoviral transfer of the 
eNOS gene also has been described.58 
To summarize the pharmacological protocol used for graft preparation and storage has the potential to 
influence the graft’s outcome. Buffered storage solutions seems to lead to better patency rates, but 
further investigation is required. 
Technical Factors  
As in every surgical procedure, technical factors play a major role during CABG and have the potential to 
affect the patency rate of bypass conduits. 
Harvesting techniques have the potential to affect graft patency. Current angiographic evidence 
suggests that endoscopic harvesting is associated with reduced SVG patency. A post-hoc analysis of the 
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PREVENT IV showed that endoscopic harvesting was associated with a significantly higher risk of vein 
graft failure at 12-18 months compared to the open technique (OR:1.41; CI 1.16-1.71, p=0.0001).4 
Similarly, in a planned sub-analysis of the Randomized ON/OFF Bypass (ROOBY) Trial the 1-year patency 
rate of endoscopically harvested SVG was significantly lower than that of veins harvested using the open 
technique (74.5% vs. 85.2%, p<0.001).59 A meta-analysis of the angiographic data of 5 trials examining 
6,504 grafts showed a significantly higher incidence and risk of graft failure in the endoscopic harvesting 
group (26.9% vs. 20.3%, p<0.0001; OR:1.38, CI 1.01-1.88).60 Another meta-analysis including 
angiographic results from 7,929 patients described a significantly higher incidence of graft stenosis and 
occlusion for endoscopically harvested saphenous veins (log-rate ratio (RR):1.19, CI 1.05-1.34, 
p=0.005  for graft stenosis and RR:1.39, CI 1.11–1.75, p=0.004 for graft occlusion).61 Although in both 
studies these differences lost statistical significance when analyses were limited to the randomized 
trials, this could be related to the reduction in statistical power as a trend toward higher graft failure in 
the endoscopic group was present even when pooling together randomized trials. The most plausible 
explanation for the reported difference is the higher degree of damage to the vascular wall induced by 
endoscopic harvesting, although not all the studies are concordant on this issue.62 Of note, studies have 
reported equivalent clinical outcomes between patients operated using endoscopic vs. open saphenous 
vein harvesting technique.63 However, in view of the discussed lack of strict correlation between clinical 
outcomes and graft patency, the angiographic data seems more relevant to clarify this issue. 
The ongoing Randomized Endo-vein Graft Prospective (REGROUP) trial64 will provide new important 
insights on this topic. 
A no-touch technique of SVG harvesting, that reduces endothelial injury10 has shown superior long-term 
patency of 83% at 16 years when compared with conventional harvesting.11  The results from a multi-
center randomized trial investigating whether the no-touch vs. conventional harvesting is associated 
with superior early SVG patency are pending.65 
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Skeletonized ITA and RA conduits have been reported to be non-inferior to pedicled with respect to 
patency.52,66 
The anastomotic technique is another important technical factor in determining patency of grafts. 
Controversy still exists on the effect of on- vs. off-pump surgery on patency rates. The ROOBY trial 
randomized 2,203 patients to on- or off-pump CABG. At 1-year follow-up, angiographic patency rates of 
the off-pump group was significantly lower than that of the on-pump (82.6% vs. 87.8%, p<0.01).67 A 
smaller European randomized trial reported similar results.68 However, two other small randomized 
trials and a post-hoc sub-analysis of the PREVENT IV study found no difference in patency rate between 
the two techniques.69–71 All the meta-analysis on the subject showed a significantly higher incidence of 
graft failure among the off-pump cases. The most recent meta-analysis of CRTs pooled angiographic 
data on 7,011 grafts and reported a OR of 1.51 for graft failure in the off-pump series (CI 1.21-1.88, 
p=0.002).72 It is plausible that differences in operator experience, study design, and enrollment criteria 
are the reasons for the discrepancies.  
Several studies compared the clinical outcomes of on- vs. off-pump CABG.73 As for the endoscopic vs. 
open harvesting comparison, due to the lack of a direct correlation between graft patency and clinical 
status, it is unlikely that the results of clinical outcome studies can be extrapolated to graft patency. 
To summarize technical factors are important in determining graft outcome. Endoscopic saphenous vein 
harvesting and off-pump technique have been correlated with lower patency rates. 
Target Vessel Factors 
Different quantitative and qualitative characteristics of the target coronary vessel have the potential to 
influence the long-term patency of bypass grafts.  
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The grafting of a vessel that is not significantly stenosed creates a situation where the flow through the 
conduit and the native coronary artery are in competition. Arterial grafts are living conduits with high 
vasoactive capacity and tend to react to this situation with a reduction in graft flow.  Low endothelial 
stress due to reduced flow is associated with reduced NO bioavailability, upregulation of several pro-
atherogenic genes in the vascular wall, and high risk of thrombosis.74 This is also a putative mechanism 
of arterial graft string sign. 
The radial and gastroepiploic arteries are the most affected by competitive flow due to their higher 
degree of contractility and vasospastic characteristics. Studies have demonstrated that radial graft 
patency is higher in patients with severe proximal stenosis. In a report by Gaudino and colleagues,16 80% 
of very-long-term RA occlusion or string sign cases occurred in patients in whom the artery was 
anastomosed to coronary arteries with stenosis ≤90%, irrespective of distal anastomosis location. This 
also applies to the gastroepiploic artery. As stated before, Suzuki and coauthors19 reported patency 
rates of 97.8%, 94.7% and 90.2% at early, 5, and 8-year follow-up when the gastroepiploic artery was 
anastomosed to a target vessels with >90% stenosis. This is in contrast to a 66.5% patency at 10-year 
follow-up when the gastroepiploic artery was anastomosed to a target vessel with <90% stenosis.75  
The ITA are also sensitive to competitive flow, although to a lesser degree. Many76 but not all77 
published studies have found that the patency of ITA grafts is directly correlated with the degree of 
proximal stenosis in the coronary target. Of note, even when chronic native competitive flow does not 
affect midterm graft patency, it influences ITA diameter.78 
The resistance of SVG appears negligible and therefore the pressure at the distal graft anastomosis is 
nearly equal to the aortic pressure, with minimal risk of developing competitive flow. Also SVG’s lack the 
ability to regulate the blood flow to the coronary territory and exhibit reduced variations in graft flow. 
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For this reason, competitive flow is a significant issue for arterial bypass, but less for venous 
conduits.79,80 
This concern is recognized in the 2011 American College of Cardiology (ACC)/American Heart Association 
(AHA) Guideline for Coronary Artery Bypass, in which arterial grafting is contraindicated in patients with 
less than sub-occlusive stenosis of the native vessel.  
Another crucial factor determining long-term patency of the graft is target vessel diameter. Goldman 
and colleagues examined the 10-year patency rates of SVG and found that if the target vessel diameter 
was >2.0mm, SVG patency was 88% as compared to a patency rate of 55% if the target vessel diameter 
was ≤2.0mm (p<0.001).8 In a report by Shah and coworkers that explored determinants of SVG failure, 
smaller target coronary vessel diameter (1.0-1.4mm, p<0.001) significantly affected graft patency.81 In a 
small randomized controlled trial, Souza and coauthors found that target vessel diameter ≥2.0mm 
impacted patency rates (OR:4.7, CI 1.4-15.4; p=0.011).39,82  
Studies have demonstrated that diffuse coronary artery disease is associated more with lower graft 
patency than focal disease.  One study using fractional flow reserve (FFR) to characterize diffuse vs. focal 
lesions found that the former were associated with an increased risk of graft failure within 6 months of 
CABG (26% vs. 7%, p=0.021).83 Diffuse atherosclerosis affects vasomotor regulation of the coronary 
target and also limits the availability of adequate landing zones for the bypass conduit. 
Prior coronary artery stenting has a similar effect as diffuse atherosclerosis, by reducing the vasomotor 
properties of the coronary vessel and limiting the areas available for anastomoses. Graft patency rates 
are significantly lower in stented coronary arteries compared with those that have not been previously 
instrumented.84 
Extensive calcification of the coronary target has even worse implications for graft failure. In addition to 
the effect on vasomotor properties and the limited areas for anastomosis described above, severely 
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calcified plaques are not amenable to suturing without performing extensive endarterectomies that 
significantly alter the architecture of the coronary artery. 
In conclusion target vessel factors can significantly impact graft patency. Competitive flow is particularly 
important for arterial grafts. Target vessel diameter, extent of atherosclerotic burden, calcification and 
previous endovascular interventions have the potential to influence graft patency. 
Intraoperative Graft Assessment and Patency  
Transit-Time Flow Measurement (TTFM) is the most commonly used method for intraoperative graft 
verification in coronary surgery.  
The area under the modulated flow trace corresponds to the mean graft flow (MGF, ml/min). The 
pulsatility index (PI), the percentage backward flow through the anastomosis (%BF) and diastolic filling 
(DF) are other important flow variables for evaluating graft function. 
Current ACC/AHA guidelines recommend TTFM for direct intraoperative quality control in CABG surgery 
(IC). 
According to the recommendations of the Joint Task Force on Myocardial Revascularization of the 
European Association of Cardiothoracic Surgery and the European Society of Cardiology, the MGF cut-off 
value to detect graft malfunction should be 20 mL/min, but different values have been reported by 
other authors (Table 2).  
The PI is obtained by dividing the difference between the maximum and minimum flow by the value of 
the mean flow. Any factor that increase the resistance to graft flow increases the PI value. According to 
the quoted European recommendations, a PI cut-off of 5 has to be used to detect graft malfunction. 
However, PI cut-off values from 3 to 5 have been reported.85  
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The %BF expresses the percentage of blood flow directed backward across the anastomotic site 
compared to the total forward flow during one cardiac cycle. The cut-off values for %BF is generally 
accepted at 3% and this index is considered particularly important in diagnosing a competition of flow or 
functional graft occlusion.85 Anyhow it has to be considered as proof of anastomosis patency. 
The DF expresses the proportion of diastolic graft flow during the entire graft flow. It is known that the 
graft flow on the right coronary artery shows a systolic prevalence and a diastolic filling by 50% 
compared to the left coronary system where it should be above 60%. Although the correlation of the DF 
with patency is poorly known, it is a possible field of future investigations on the systolic function of the 
right ventricle. 
TTFM is characterized by a fairly high specificity with a poor sensitivity that leads to a low positive 
predictive value and high negative predictive value.86 Standardization of factors such as the systemic 
arterial pressure at which measurements are taken and the position of the probe is extremely important 
to increase TTFM sensitivity.86 
Limited evidence exists on the correlation between TTFM values and graft patency, as most of the 
published studies have clear selection bias, used different definitions and cut-off values, and had 
different follow-up. All published series are probably underpowered to detect moderate correlations. A 
small randomized study on the subject showed that routine TTFM does not improve 1-year graft 
patency but did find a significant correlation between low TTFM flow and graft occlusion at 1 year.87 A 
retrospective angiographic analysis of two randomized controlled trials, the Best Bypass Surgery trial 
and the Copenhagen Arterial Revascularization Randomized Patency and Outcome trial on 982 grafts 
found a 4% decrease in graft failure odds for every 1 mL/min increase in MGF (OR:0.96, CI 0.93-0.99; 
p=0.005).88 
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The lack of sensitivity of the method may be partially overcome by increasing the myocardial oxygen 
demand by injecting a bolus of 20 mcg/Kg of dobutamine.89 The dobutamine test can be helpful in 
evaluating a reversal of a flow competition between two branches of a composite conduit produced by 
an unbalanced severity of the native stenosis. It is additionally useful in predicting patency of a single 
ITA at risk of functional occlusion (very high PI and very low MGF and very high % BF).85 
Integration with intraoperative imaging (Figure 3) in order to visualize the anastomosis morphology is 
another mean of increasing TTFM sensitivity.  It has been demonstrated that when TTFM is coupled with 
high-resolution ultrasound imaging the diagnostic accuracy can increase to 100%.90 
Fluorescence coronary angiograms using indocyanine green is another imaging method for 
intraoperative evaluation of graft function that can potentially be coupled with TTFM, but very few data 
have been reported to date.91 
Finally, it must be noted that most of the published TTFM data refers to the ITA and the saphenous vein. 
A recent comparative analysis showed that those two types of grafts have fairly overlapping TTFM 
results.85 Very few data exist for the other conduits. 
To summarize TTFM is an important tool to intraoperatively evaluate graft function and can potentially 
predict long-term graft patency. However, concomitant use of imaging techniques or of pharmacological 
tests is necessary in order to improve TTFM accuracy. 
Secondary Prevention  
Post-operative antiplatelet and lipid-lowering agents continue to be the mainstay of secondary 
prevention after CABG surgery. Inhibition of platelet activation after CABG helps maintain graft patency 
and prevent atherothrombotic complications. According to a recent AHA scientific statement on 
secondary prevention after CABG surgery, aspirin should be administered pre-operatively and within 6 
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hours after CABG in doses of 81-325mg daily. It should then be continued indefinitely to reduce graft 
occlusion and major vascular events (Class I, Level of Evidence A; IA). For aspirin-treated patients, 
current guidelines recommend continuing antiplatelet therapy prior to surgery, except for patients at 
high bleeding risk. However, there is limited randomized evidence to support one strategy over the 
other,92 and the recently published Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) 
trial,93 enrolling 2,100 patients did not resolve this uncertainty. Notably, patients were enrolled into the 
study if they had not been taking aspirin regularly before the trial or had stopped taking aspirin at least 
four days before CABG surgery.93  
There is a discrepancy among current US and European guidelines on the recommended dose of aspirin 
for long-term treatment after CABG: while the former suggest considering a higher (325mg daily) rather 
than a lower (81mg daily) aspirin dose, "presumably to prevent aspirin resistance" (IIaA), the latter 
recommend a low-dose (75-100mg daily) aspirin in all patients (IA). Aspirin "resistance" is an ill-defined 
phenomenon, largely explained by non-compliance, a pharmacodynamic interaction of some 
nonsteroidal anti-inflammatory drugs with low-dose aspirin, or reduced systemic bioavailability of some 
enteric-coated formulations.94 A more likely explanation for the impaired efficacy of low-dose aspirin in 
the early post-operative period following CABG surgery is represented by a transient increase in platelet 
turnover95 that may limit the duration of platelet TXA2 inhibition because of accelerated renewal of the 
drug target. Consistent with this hypothesis, two independent groups have shown that multiple daily 
doses of aspirin (81mg qid or 100mg bid) overcome impaired platelet inhibition in response to a 
conventional once-daily regimen, and are more effective in suppressing platelet TXA2 production than 
higher od doses (200 to 325mg) four to seven days after CABG surgery. Clearly, a randomized clinical 
trial is needed to test the hypothesis that more frequent aspirin dosing reduces premature graft 
occlusion and prevents major vascular events. The high rate of death and thrombotic complications in 
the recent ATACAS trial, particularly non-fatal myocardial infarction, detected within the first 30 days 
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after CABG (13.8% vs. 15.8% in the aspirin vs. the placebo group, respectively (RR:0.87, CI, 0.71-1.07; 
p=0.20)93 outlines the limitations of current antithrombotic strategies in this setting and emphasizes the 
need for additional clinical studies. 
Following off-pump CABG, dual antiplatelet therapy is recommended for 1 year with low-dose aspirin 
(81-162mg daily) and clopidogrel (75mg daily) to reduce graft occlusion (IA). Dual antiplatelet therapy 
for 1 year after on-pump CABG may be considered in patients without recent acute coronary syndrome 
(ACS), but the benefits are not well established (IIbA). After completion of the Platelet Inhibition and 
Patient Outcomes (PLATO) study, a phase-3 trial of ticagrelor vs. clopidogrel in aspirin treated ACS 
patients96, the investigators performed a post-hoc analysis of the 1,261 patients who underwent CABG 
within 7 day of receiving treatment.97 In this sub-group, ticagrelor was associated with a non-significant 
reduction in the primary end-point at 1-year compared with clopidogrel (10.6% with ticagrelor vs. 13.1% 
with clopidogrel; HR:0.84, CI, 0.60-1.16; p=0.29), and a significant reduction in cardiovascular mortality 
(4.1% vs. 7.9%, respectively; HR:0.52, CI, 0.32-0.85; p<0.01), with no significant difference in CABG-
related major bleeding between the two P2Y12 blockers (81.2% vs. 80.1%, respectively; HR:1.01, CI 0.90-
1.15; p=0.84).97 However, no additional studies have examined prospectively the potential superiority of 
ticagrelor or prasugrel vs. clopidogrel in a representative population of patients undergoing CABG. 
Elevated low-density lipoprotein (LDL)-cholesterol levels accelerate the process of SVG disease after 
CABG, by favoring the development of intimal hyperplasia and atheromatous plaques. Statins are highly 
effective in reducing plasma LDL-cholesterol concentrations independently of the baseline level. 
Moreover, their efficacy and safety in reducing important vascular outcomes has been convincingly 
established by numerous randomized clinical trials in approximately 174,000 coronary artery disease 
patients participants and a meta-analysis of their individual data.98 Overall, in this meta-analysis, among 
the 27 trials included, statins reduced the risk of major vascular events by 21% for each mmol/L 
reduction in LDL-cholesterol (RR:0.79, CI 0.77-0.81; p<0.0001), with significant reductions in both 
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women and men. Moreover, similar proportional reductions in risks of major vascular events per 
mmol/L LDL-cholesterol reduction independently of the baseline characteristics of the randomized 
participants, including pre-treatment LDL cholesterol level, history of CHD, and estimated 5-year risk of 
major vascular events were demonstrated.98  
Statins have been shown to reduce the development of SVG disease by inhibiting neo-intimal formation 
and VSMC proliferation. Thus, the Post-CABG trial demonstrated that lowering LDL-cholesterol levels to 
<100 mg/dL reduced both cardiovascular events and the progression of atherosclerosis in native 
coronary arteries and SVG (27% vs. 39% aggressive vs. moderate cholesterol-lowering treatment, 
respectively; p<0.001).99 Although the benefits of more aggressive lipid lowering by high-intensity statin 
therapy to LDL levels <70 mg/dL in further reducing the risk of major vascular events are well 
established98, specific data on patients undergoing CABG are sparse and further research is needed.  
Despite the remarkable database supporting the efficacy and safety of long-term statin therapy,98 it 
remains underused after CABG with declining patient adherence. According to the recent AHA 
statement, essentially all CABG patients should receive long-term statin therapy, starting in the pre-
operative period and restarting early after surgery in the absence of contraindications such as liver 
disease (IA). High-intensity statin therapy (e.g., atorvastatin 40-80mg, rosuvastatin 20-40mg daily) 
should be administered after CABG surgery to all patients <75-years of age (IA). Moderate-intensity 
statin therapy should be prescribed to those patients who are intolerant of high-intensity therapy and to 
those at greater risk of drug-drug interactions, such as CABG patients >75-years of age (IA).  
The recent IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) found a 
8.8% (CI 3.1–14.6) lower absolute risk of cardiovascular death, major coronary event or stroke at 6 years 
by adding ezetimibe to statin therapy in patients with prior CABG.100 
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Although CABG using arterial grafts might be associated with a lesser degree of downstream coronary 
and conduit disease progression, there is no evidence that this may dictate a different approach to 
secondary prevention. 
To summarize post-operative therapy with antiplatelet and lipid-lowering agents remain the 
cornerstone of secondary prevention after CABG surgery. The role of dual antiplatelet therapy and of 
ezetimibe remain to be determined. 
Conclusion 
Graft failure is a complex phenomenon that occurs in a substantial proportion of CABG conduits. 
Biological mechanisms, target vessel characteristics, as well as surgical technique, and type of graft used 
all play a role in determining failure. The correlation between vascular risk factors and graft patency 
needs further investigation. The clinical consequences of graft failure seem to be dependent on the type 
and location of the failed graft and are still poorly characterized. Pharmacological prevention with 
antiplatelet and lipid-lowering agents is associated with better clinical outcome after CABG and has the 
potential to reduce the incidence of graft occlusion. Finally, further studies are need on the possibility 
that intraoperative assessment of graft flow by TTFM and imaging techniques can reduce the incidence 
of graft failure.  
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Figure Legends 
Figure 1: Pathophysiology of early and late graft failure.  
Different biological mechanisms contribute to the pathophysiology of vascular graft failure. While early 
failure is linked to technical factors resulting in endothelial injury and activation with subsequent 
thrombosis, late failure is more commonly the result of atherogenesis and plaque rupture. In the early 
stages following graft implantation, endothelial injury due to surgical manipulations and endothelial cell 
activation (e.g., due to hemodynamic stress or transient ischemia) can result in the release of pro-
thrombotic and pro-inflammatory molecules (e.g. vWF, CD40L, tissue factor) that trigger the thrombotic 
cascade resulting in acute occlusion. Impaired endothelial function (characterized by poor NO 
bioavailability) also promotes a pro-inflammatory and pro-thrombotic phenotype, whereas local release 
of cytokines such as PDGF promotes cell migration and neo-intima formation. On the contrary, late 
failure (months to years after surgery) is associated with atherosclerotic vascular disease. Systemic 
biological factors (e.g., diabetes, smoking, hypercholesterolemia) and local biological mechanisms (e.g., 
increased oxidative stress, vascular inflammation, endothelial dysfunction) all contribute to the initial 
plaque formation and subsequent progression until the advanced disease stages of significant luminal 
stenosis or plaque rupture which results in thrombosis and occlusion to blood flow. 
CD40L: cluster of differentiation 40 ligand, LDL: low-density lipoprotein, NO: nitric oxide, PAI-1: 
plasminogen activator inhibitor 1, PDGF: platelet-derived growth factor, ROS: reactive oxygen species, 
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TxA2: Thromboxane A2, VCAM-1: Vascular cell adhesion molecule 1, VSMC: vascular smooth muscle 
cells, vWF: von Willebrand factor. 
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Figure 2: Schema of molecular mechanisms of smooth muscle contraction and the relaxation in the 
coronary artery bypass grafts (Reproduced from He GW, Taggart DP. Ann Thorac Surg. 2016;102:659-68 
with permission).  
Contraction: Contraction is the summation of myosin light chain kinase (MLCK) and myosin light chain 
phosphatase (MLCP) activity.  Ca2+ influx via calcium channels in the membrane (voltage-operated 
channel [VOC] and receptor-operated channel [ROC]) and Ca2+ release from intracellular stores in the 
sarcoplasmic reticulum (SR) via phospholipase C (PLC)-mediated hydrolysis of phosphotidyl inositol 
bisphosphate, yielding inositol triphosphate (IP3) result an increase in intracellular Ca2+.  The Ca2+ 
interacts with calmodulin, forming a Ca2+-calmodulin complex which activates MLCK that phosphorylates 
myosin light chain, allowing for force generation. Vasoconstrictors such as the agonists of α-
adrenoceptor (α), thromboxane A2 (TxA2), endothelin-1 (ET), etc., stimulate G-protein coupled receptors 
(GPCRs) directly opening the ROC causing Ca2+ influx, or through the production of second messengers 
such as IP3 causing release of the stored Ca2+.  Contraction can also be mediated in Ca2+-sensitization 
mechanism.  Rho-kinase becomes activated via the activated RhoA protein, which subsequently 
phosphorylates MLCP, rendering the enzyme inactive and incapable of de-phosphorylating MLC.  
Relaxation: Relaxation occurs with MLCP dephosphorylating MLC. This can be accomplished through 
various mechanisms.  For example, it can be via blockage of Ca2+ influx by calcium channel blocker (CCB) 
to decrease the intracellular Ca2+.  The antagosists of specific vasoconstrictors such as the antagonists 
ofα-adrenoceptor, TxA2, ET, etc, inhibit the ROC associated with GPCRs. Nitrovasodilators via releasing 
nitric oxide (NO) stimulates soluble guanylate cyclose (sGCs), which increases synthesis of cGMP from 
GTP.  Increased cGMP level inhibits VOC and ROC through protein kinase G (PKG) pathways.  NO-cGMP 
also interacts with Rho Kinase pathway via cGMP regulated protein kinases (cGK), interferes the MLC 
and phospho-MLC acitivity, and finally relaxes the smooth muscle.  The Rho Kinase inhibitor inhibits Rho 
Kinase pathway and the phosphodiesterase (PDE) inhibitors increase cGMP level via inhibiting cGMP－
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5’GMP activity, relaxing the vessel.  Potassium channel openers (K+ openers) open the potassium 
channels such as calcium-sensitive potassium channels (KCa), cause efflux of K+ and hyperpolarizes the 
membrane potential (Em). The membrane hyperpolarization decreases intracellular Ca2+ levels by 
inhibiting Ca2+ influx through VOC and favors the re-uptake of Ca2+ into intracellular stores and extrusion 
of Ca2+ from the cell, resulting in relaxation. Prostacyclin (PGI2) raises cAMP levels in the cytosol and via 
activation of the protein kinase A pathway leads to relaxation.  
This schema also shows that each vasodilator relaxes blood vessel in a specific pathway, although there 
are some interactions between the pathways.  A possible protocol for relaxation of coronary artery 
bypass grafts is to combine two vasodilators that relax the vessel in different pathways. 
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Figure 3: Intraoperative graft verification on a 72 year-old male, previous PCI on LAD; recent ACS with 
occluded LAD. (Courtesy Prof. G. Di Giammarco) 
(A): 2-D image of LIMA to LAD grafting; (B): Color Flow Mapping of the same graft; (C): MGF of LIMA to 
LAD below cut-off value (15ml/min); (D): dobutamine test of the same graft with three-fold increase of 
MGF at double product of 14900.  
PCI: percutaneous coronary intervention; LAD: Left anterior descending artery; ACS: acute coronary 
syndrome; LIMA: left internal mammary artery; MGF: mean graft flow 
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Tables 
Table 1. Coronary artery bypass graft patency rates 
Conduit Early patency (1-year) Mid-term patency (5-7 years) Late patency (≥10 years) 
Saphenous Vein Graft 81-97.9% 75-86% 50-60% 
Internal Thoracic Artery 93-96% 88-98% 85-95% 
Radial Artery 89-92% 90-98% 89-91% 
Right Gastroepiploic Artery 92-97% 80-90% 62% 
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Table 2. Major series on intraoperative graft verification 
Author, year, journal, study type Patient group Study Aim Results Comments 
D’Ancona et al.  
2000, European J Thorac Cardiovasc Surg 
 
Retrospective Study 
409 off- pump CABG patients via 
median sternotomy with 1,145 grafts 
tested using TTFM 
Clinical application of TTFM for 
the detection of anastomotic 
failure  
41 grafts revised in 33 patients  
34 (91.9%) were revised for both low flow and 
abnormal flow curve patterns 
No information about mid-term angiographic  
patency in the three conduits with altered flow 
and  
no technical problems at the revision.  
Gaudino et al.  
2003, J Thorac Cardiovasc Surg 
 
Prospective Study 
21 composite arterial conduits 
evaluated with intra-operative 
dobutamine bolus injection after 
coronary grafting  
Intraoperative evaluation of 
coronary flow reserve 
Double product after test 12087±2395 (range); 
Flow reserve:  
Main stem of the composite conduit: 2.1±0.6,  
LIMA branch: 2.2±0.9,  
RIMA branch: 2.1±0.9  
Intraoperative injection of dobutamine increases 
the flow in the Y thoracic graft by more than two 
times, not only in the main stem but also in each 
branch. This finding attests to the large flow 
reserve of Y thoracic conduits. 
Kim et al.  
2005, Ann Thorac Surg  
 
Retrospective study 
58 arterial off-pump CABG patients 
evaluated with intraoperative TTFM 
and postoperative angiography 
Validity of intraoperative TTFM 
for the prediction of graft flow 
abnormalities 
Criteria to predict abnormal grafts as systolic 
dominant flow curve: MGF <15 ml/min; PI>3 in 
the left coronary territories, and >5 in the right 
coronary territories and %BF >2%. 
 
Sensitivity and specificity of TTFM to detect 
graft flow abnormality were 96.2% and 76.9%, 
respectively  
Small sample size and diagnostic accuracy 
evaluated without multivariate and ROC analysis.  
Di Giammarco et al. 
2006, J Thorac Cardiovasc Surg 
 
Retrospective study 
157 patients evaluated with 
intraoperative TTFM and angiography  
Predict postoperative graft 
patency in coronary surgery by 
means of TTFM 
Group A: 266 grafts patent; Group B: 38 grafts 
failed 
MGF (OR, 0.86; P=0.002), PI (OR, 1.3; P=0.031), 
%BF (OR, 1.1; P=0.041) values were confirmed 
to be predictive parameters of graft failure, 
even in case of venous grafts. 
Cut-off, sensitivity, specificity and PPV for MGF: 
15, 0.87, 0.87, 0.95; PI: 3:0, 0.66, 0.67, 0.66; 
%BF3: 1 0, 0.67, 0.53, respectively 
The retrospective nature of the study is a limiting 
factor. 
 
Tokuda et al. 
2008, Ann Thorac Surg 
 
Retrospective study 
123 patients with postoperative 
angiography were divided into two 
groups:  
A (occluded grafts) and B (patent 
grafts) 
TTFM’s ability to predict mid-term 
graft failure  
 
Group A vs. Group B 
MGF: 26.5±14.7 vs. 47.7±30.2, P=0.01; 
%BF: 6.13±9.47 vs. 2.30±5.02, P<0.05.  
 
Odds Ratio (OR) of midterm graft failure 
MGF: OR:0.96 (0.93-0.98), P<0.01; 
PI: OR:1.14 (0.98-1.40) P=0.12; 
%BF: OR:1.08 (1.01-1.17) P=0.15; 
Time to angiography: OR:1.06 (1.01-1.13) 
P<0.05 
Small sample size limited the ability of logistic 
regression analysis to detect risk factors. 
Postoperative angiography was not performed in 
all patients. 
 
Kieser et al. 
2010, European J Thorac Cardiovasc Surg 
 
Prospective study 
336 patients evaluated with TTRM 
including 990 arterial grafts 
TTFM parameters’ ability to 
predict MACE in the postoperative 
period 
25 (7.4%) patients suffered MACEs 
postoperatively:  
recurrent angina: 6/336 (1.8%), perioperative 
myocardial infarction: 9/336 (2.7%), PCI: 6/336 
ROC analysis was not performed to establish cut-
off values. 
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CABG: coronary artery bypass graft, HR-ECUS: high-resolution epicardial ultrasonography, LAD: left anterior descending, LIMA: left internal mammary artery, MACE: 
major adverse cardiac events, MGF: mean graft flow, NPV: negative predicted value, PCI: percutaneous coronary intervention, %BF: percentage backward flow, PI: 
pulsatility index, PPV: positive predicted value, RIMA: right internal mammary artery, ROC: receiver operating characteristic, TnI: troponin I; TTFM: TransitTime flow 
measurement.  
 (1.8%), early re-operation 4/336 (1.2%) and/or 
perioperative death: 16/336 (4.8%).  
The variables PI >5, age, and admission status 
were all significant predictor variables of MACE 
(P < 0.05). 
Di Giammarco et al. 
2014, European J Thorac Cardiovasc Surg 
 
Retrospective study 
333 CABG with a total of 717 grafts 
being verified by means of both 
TTFM and HR-ECUS  
Compare TTFM combined with 
HR-ECUS vs. TTFM alone for 
diagnostic accuracy of 
intraoperative graft evaluation  
 
Among 678 grafts considered to be functioning 
at TTFM, 3 (0.4%) were failing at HR-ECUS. HR-
ECUS confirmed the functional status of the 
remaining 675 grafts already demonstrated by 
TTFM. Among them, 8 showed high TnI release, 
whereas the remaining 667 had no high TnI 
release. In 2 of 39 grafts malfunctioning at 
TTFM, HR-ECUS confirmed the graft failure. 
Surgical inspection of the anastomosis during 
redo procedure showed a technical error 
leading to define those 2 grafts as ‘true 
positive’ on the basis of either direct vision and 
improved post-redo TTFM parameters. Finally, 
in 35 cases, HR-ECUS did not confirm a TTFM 
diagnosis demonstrating full patency of the 
anastomosis; these grafts had an uneventful 
clinical course. PPV, NPV, and diagnostic 
accuracy of combined TTFM and HR-ECUS 
intraoperative graft verification procedure: 
100%, 99%, and 100%, respectively. 
Lack of angiographic controls. 
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